Sotatercept

[1]Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384 (13) :1204-1215. |[2]Raje N, et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010 Oct;12 (5) :586-97.|[3]Abdulkadyrov KM, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165 (6) :814-23.|[4]Sherman ML, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013 Nov;53 (11) :1121-30. |[5]Iancu-Rubin C, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013 Feb;41 (2) :155-166.e17.